📰 Selective Targeting News
Selective Targeting News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Selective Targeting. Real-time updates on events, politics, business and more.
April 24, 2024
BOSTON, April 24, 2024 -- Cue Biopharma, Inc. , a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells,...
April 8, 2024
BOSTON, April 08, 2024 -- Cue Biopharma, Inc. , a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, today...
April 2, 2024
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced
April 2, 2024
BOSTON, April 02, 2024 -- Cue Biopharma, Inc. , a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells,...
November 3, 2023
Overall response rate of 47% and disease control rate of 65% in first line recurrent/metastatic HNSCC patients treated with CUE-101 and KEYTRUDA® ORR of 56% in patients with low expression of...
September 27, 2023
BOSTON, Sept. 27, 2023 -- Cue Biopharma, Inc. , a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T...
September 27, 2023
BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
September 26, 2023
Completed enrollment of patient expansion cohort of 20 patients at the RP2D of 4 mg/kg in combination with KEYTRUDA® (pembrolizumab) in first line...
July 12, 2023
Uttar Pradesh DGP Vijaya Kumar says he is focused on getting criminal elements convicted through courts
June 14, 2023
BOSTON, June 14, 2023 -- Cue Biopharma, Inc. , a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T... | June 14, 2023